2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. KMO

KMO

Kynurenine-3-monooxygenase

Kynurenine-3-monooxygenase (KMO) is an enzyme that plays a crucial role in the kynurenine pathway. It catalyzes the hydroxylation of kynurenine to 3-hydroxykynurenine, using molecular oxygen and NADPH as cofactors. This enzyme is mainly expressed in the liver and brain. In the brain, the kynurenine pathway is involved in the regulation of neurotransmitter levels and immune responses. Dysregulation of Kynurenine-3-monooxygenase activity has been implicated in various neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, and depression[1][2][3].

KMO Related Products (3):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12347
    Ro 61-8048
    		Inhibitor 99.76%
    Ro 61-8048 is an orally active and selective inhibitor of kynurenine 3-hydroxylase, with an IC50 of 37 nM. Ro 61-8048 provokes a significant increase of extracellular kynurenic acid concentrations.
    Ro 61-8048
  • HY-112179
    GSK180
    		Inhibitor 99.04%
    GSK180 is a selective, competitive, and potent inhibitor of kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism (IC50, ~6 nM), but shows negligible activity against other enzymes on the tryptophan pathway. GSK180 rapidly changes levels of kynurenine pathway metabolites, and acts as a useful tool to probe the therapeutic potential of KMO inhibition.
    GSK180
  • HY-15500
    JM6
    		Inhibitor
    JM6 is a weak kynurenine 3-monooxygenase (KMO) inhibitor with an IC50 of 19.85 μM for mouse KMO. JM6 can be used for Alzheimer's diseases research.
    JM6